M quired clonal bone marrow (BM) disorders, charac-
terized by quantitative and qualitative defects of hematopoiesis. In the elderly, they are rather common diseases, with incidence rates of about 25 in 100,000 per year in people over the age of 70.' In the majority ofcases, the outcome is fatal within months to years because of infections, hemorrhages, or transformation into acute myeloid leukemia (AML).24 Despite numerous clinical trials, no standardized therapy can currently be offered to MDS patients. Aggressive antileukemic regimens or allogeneic BM transplantation, which may induce long-term remission^,^-^ are not applicable to the majority of patients because of their advanced age. Therefore, treatment is often restricted to supportive measures, including blood component therapy and antibiotics.
BM cells from MDS patients can be induced to differentiate in vitro by various agents such as retinoids, vitamin D,, glucocorticoids, interferons, hexamethylene bisacetamide, low doses of cytosine arabinoside or 5-azacytidine, and hematopoietic growth factors.*'I6 The clinical efficacy of 13-cis retinoic acid ( 13-CRA) in MDS has been evaluated in several pilot series and in two randomized controlled trials. Clark et all7 randomly assigned MDS patients to receive either 13-CRA plus supportive therapy or supportive therapy alone. Among patients with nonsideroblastic anemia, they found a significant difference in survival between the treated and the control group. In contrast, Koeffler et alls who performed a double-blind placebo-controlled trial, failed to show any beneficial effect of 13-CRA in MDS. All-trans retinoic acid (ATRA), the natural isomer of 13-CRA, has recently been shown to be an effective agent in acute promyelocytic leukemia (APL), with induction of complete remissions in the majority of patient^.'^-^' Clinical response occurs without BM aplasia and is caused by differentiation of leukemic cells into phenotypically mature myeloid cells. Of interest, Visani et a122 recently reported two patients with refractory anemia (RA) with excess blasts mission. Three patients had a minor response, manifested by either reduction in transfusion requirements (2 patients) or increase in neutrophil and platelet counts (1 patient). During the study period, 5 patients progressed to more advanced stages of MDS or overt leukemia. Three patients with chromosomal abnormalities receiving ATRA for a period of I O to 12 weeks retained their cytogenetic marker after completion of treatment. Side effects of ATRA primarily affected the skin and mucous membranes, with 13 of 1 5 patients having at least low-grade dermatologic toxicity. In 2 cases, treatment had to be prematurely stopped because of intolerable conjunctivitis or progressive neurologic symptoms. These data suggest that ATRA has little effect on MDS. The lack of response of MDS patients, as compared with those with APL, may be attributed to the absence of the t(l5;17) translocation that seems to be a prerequisite for clinical efficacy of ATRA.
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(RAEB) who both responded to treatment with ATRA with a marked increase in medullary erythropoiesis and improvement of peripheral hemoglobin concentrations. To examine the efficacy of ATRA in MDS, we performed a pilot study in which 15 patients with various stages of MDS were treated with increasing doses of ATRA (30 to 90 mg/m2/d) over a period of 3 months.
MATERIALS AND METHODS

Patients.
Informed consent according to institutional guidelines was obtained from all patients entering the study. Between July 199 1 and February 1992,14 patients with primary MDS and I patient with secondary MDS (after prolonged treatment with melphalan for multiple myeloma) were treated with ATRA. All patients met the criteria proposed by the French-American-British (FAB) Cooperative Group for diagnosis of MDS." The median time from diagnosis to initiation of ATRA treatment was 13 months (range, 0.5 to 84). A total of 5 patients had previously been treated with other therapies (low-dose cytosine arabinoside, aggressive chemotherapy, or hematopoietic growth factors). Morphologic diagnoses at study begin were RA in 4 cases, RA with ring sideroblasts (RARS) in 2 cases, RAEB in 7 cases, and RAEB in transformation (RAEB/T) in 2 cases. Of those, 9 patients were men, and 6 were women. Their median age was 69 years (range, 42 to 85). Patients included were required to have one or more of the follow- Treatment schedule. ATRA was administered in 10-mg gelatine capsules, kindly provided by Hoffmann-La Roche (GrenzachWyhlen, Germany). The treatment period was planned to last 3 months. Therapy was started at an ATRA dose of 30 mg/m2/d, administered orally as two doses of 15 mg/m2 every 12 hours. The ATRA dose was increased to 60 mg/m2/d after 4 weeks and to 90 mg/m2/d after 8 weeks. During the study period, no other pharmacologic therapy that might influence hematologic parameters was administered, and blood cell transfusions were restricted to patients with symptomatic anemia. The study protocol was reviewed and approved by the Ethical Committee of the University Hospital of Diisseldorf, Germany.
Monitoring of patients included physical examination, complete blood cell counts, liver and renal function tests, cholesterol and triglyceride levels, urine analysis and coagulation tests before treatment and thereafter every 2 weeks during ATRA administration. BM aspirates and biopsies were routinely performed on days I and 90 of study and evaluated for blast cell count, presence of cytologic abnormalities, and cellularity. In 3 of4 patients presenting with an abnormal karyotype, BM chromosomal studies were repeated at the end of the study. Cytogenetic analysis 
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RESULTS
Hematologic responses.
A total of 10 out of 15 patients completed 3 months of ATRA therapy (Table 2 ). In 3 patients (nos. 3, 8, and 15), treatment had to be prematurely stopped after 1, 7, and 10 weeks because of side effects of ATRA and/or transition of MDS into overt AML; 2 additional patients (nos. 7 and 14; morphologic diagnoses, RAEB and RAEB/T, respectively) died after 8 and 10 weeks of therapy from septic complications and transformation of MDS to AML, respectively.
The effect of ATRA on transfusion requirements, neutrophil and platelet counts, and medullary blast cell infiltration is shown in Fig 1. None of the patients obtained a CR or PR. Three patients (nos. 1, 5, and IO) had MR. Of these, 1 patient with a diagnosis of RAEB (no. 10) showed a normalization of granulocyte values, significant increase in platelet counts (from 20 X 109/pL to 53 X 109/pL), and slight reduction in medullary blast cell percentage (from 10% to 7%). The patient's anemia, however, remained unchanged over the course of study (Fig 2) . After discontinuation of ATRA, the neutrophil and platelet count fell to pretreatment values.
For In addition, 2 patients (nos. 1 and 5; morphologic diagnoses, RA and RARS, respectively) responded to ATRA treatment with a reduction in transfusion requirements. However, it should be noted that I of these patients (no. I ) had been treated with aggressive chemotherapy 9 weeks before starting the ATRA protocol (Fig 3) . Therefore, it can not be excluded that the decrease in transfusion requirements, which lasted for 9 months, was primarily caused by the preceding chemotherapy and may not reflect a response to ATRA. In both patients, no improvement in other hematologic parameters was seen during ATRA treatment. Patient no. 5 received a second course of ATRA (outside the study protocol) after 14 months because his hemoglobin values deteriorated. He responded again with rising hemoglobin concentrations (Fig 4) .
Of the patients studied, 6 were classified as having stable disease (nos. 3,4, 6, 7, 9, and 12); 2 ofthem experienced a transient increase in both platelet and neutrophil counts for a period of 5 and 7 weeks, respectively. While on protocol, 5 patients showed an increasing proportion of medullary blast cells. Of these, 1 patient (no. 2), with an initial diagnosis of RA, progressed to RAEB; I patient with RAEB (no. 1 I ) evolved to RAEB/T, and 3 patients (nos. 13, 14, and 15; among them 2 cases of RAEB/T) developed overt AML. ATRA treatment was terminated after 1 week in 1 patient (no. 8) because of severe conjunctivitis, and this patient's data were considered inevaluable.
Concerning BM morphology, we observed 1 patient with RARS (no. 6) in whom ATRA treatment was accompanied by a marked reduction in the proportion of ring sideroblasts (from 61% to 18%). However, this change did not translate into an increase in hemoglobin values. In other patients, dysplastic features of hematopoietic cells remained unchanged after therapy. None of our patients showed a significant decrease or increase in BM cellularity on trephine biopsies performed at the end of the study. Three patients with chromosomal abnormalities receiving ATRA for a period of 10 to 12 weeks (nos. 5, 13, and 14), retained their cytogenetic marker after completion of treatment.
ATRA-related side effects are detailed in Table 3 . Changes of the skin and mucous membranes were encountered in 13 of I5 patients (86%) and consisted of erythema and hyperkeratosis, cheilitis, rhagades, conjunctivitis, or nail dystrophia. One patient (no. 8) developed severe conjunctivitis within 7 days of initiation oftherapy and had to be taken off the study. Three patients (nos. 4, 6 , and 15) complained of myalgias that were associated with slight elevations of serum creatine kinase activity. At an ATRA dosage of 90 mg/m2/d, 1 of these patients (no. 4) developed a dolent tumor of the right biceps muscle at the time of completion of the study. The tumor gradually resolved in a few weeks time. In another patient (no. 3), ATRA treatment had to be stopped because of progressive neurologic symptoms (headaches and confusion). Other side effects observed in our patients included fatigue (2 cases), nausea and vomiting (1 case), diarrhea ( 1 case), and joint pain (2 cases). While on protocol, approximately 50% of the patients experienced transient asymptomatic elevations of serum triglycerides, whereas biochemical signs ofliver cell damage or renal toxicity were not noted.
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DISCUSSION
MDS are characterized by impaired proliferation and maturation of hematopoietic precursor cells, resulting in ineffective blood cell production. Complications of BM failure are important causes of death and often occur before transformation of MDS into AML. There has been much interest in applying differentiation-inducing agents in these disorders,I6 particularly as the hematopoietic cells in MDS are arrested at a more mature developmental stage than cells from AML patients. When assessed by various in vitro systems, retinoids possess strong differentiation-inducing activity on cultured human MDS and AML cell^.^^'^,^^ Clinical activity of 13-CRA has been documented by several case reports, and at least one larger trial described a survival advantage for patients with nonsideroblastic RA treated with 1 3-CRA.I7 Recent comparative studies of the effect of different retinoids on leukemic cells from APL patients have shown that ATRA exerts its differentiation-inducing effect at significantly lower concentrations than 1 3-CRA.27 In For personal use only. on October 23, 2017. by guest www.bloodjournal.org From view of the favorable results of ATRA treatment in APL, it appeared promising to us to examine the effectiveness of ATRA in MDS.
In this study, 15 patients with various subtypes of MDS were treated with increasing doses of ATRA (30 to 90 mg/ m2/d) over a maximum period of 3 months. The ATRA dosage was escalated because previous studies of MDS suggested a correlation between the retinoid dose and clinical effectivenes~.~~'~~ At the highest dose level, MDS patients in our study received twice the amount of ATRA required for successful treatment of APL.I9 Except for 1 case in which ATRA treatment had to be stopped after 1 week because of unacceptable side effects, all patients received the test drug for at least 7 weeks, with 10 patients being treated The marginal hematologic responses that we achieved in some of our MDS patients might have been induced by Based on the data of this trial, we surmise that ATRA has little clinical effect on MDS. Recently, Ohno et a145 published the results of a multiinstitutional study of 23 MDS patients treated with ATRA at an oral dose of 45 mg/m2/d. Clinical results were very similar to ours, and ATRA was considered only minimdly effective in MDS. Further studies will have to clarify whether treatment results can be improved by combining ATRA with other differentiationpoietic growth factors which have shown synergistic effects with ATRA in vitr0.4"~' Recently, 9-cis-retinoic acid (9-CRA) was found to be moderately more potent than ATRA as far as its effects on normal and leukemic hematopoiesis in vitro are c0ncerned.4~ Although both 9-CRA and ATRA can directly bind the RAR with similar affinity, 9-CRA alone directly binds to the retinoid X receptors (RXR), suggesting that biologic differences exist &tween the= retinoids that might be exploited clinically. The 9-CRA-RXR complex might activate a unique set of differentiation-related genes that are not as efficiently transactivated by the be capab1e Of metabo1izing ATRA to this may not be as efficient as exogenously providing the ligand to the CellS. Therefore, even though our study could not show clinical efficacy of ATRA, other retinoids may still turn out to be useful in the treatment of MDS. For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
